Novartis: Metabolic Syndrome trials
The registry lists 12 Metabolic Syndrome studies with Novartis as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 2 2Phase 3 1Phase 4 8No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic SyndromeCompletedNCT03440736Phase 4Results posted
- To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes TherapiesCompletedNCT01068860Phase 2Results posted
- Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic HypertensionCompletedNCT00797316Phase 4Results posted
- The Effect of Fluvastatin XL® Treatment in Patients With Metabolic SyndromeCompletedNCT00664742Phase 4Results posted
- Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic SyndromeTerminatedNCT00542269Phase 4Results posted
- Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic SyndromeCompletedNCT00417170Phase 2Results posted
- Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic SyndromeCompletedNCT00394745Phase 3
- Efficacy of Fluvastatin and Fenofibrate in Comparison to Simvastatin and Ezetimibe in Patients With Metabolic SyndromeCompletedNCT00385658Phase 4
- Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial Function In Hypertensive Subjects With The Metabolic SyndromeCompletedNCT00241150Phase 4
- Cardiovascular Risk Evaluation in Clinical Practice in Metabolic Syndrome PatientsCompletedNCT00171548
- A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic SyndromeCompletedNCT00170937Phase 4
- Other Effects of Fluvastatin Are Investigated in Patients With Metabolic SyndromeCompletedNCT00138528Phase 4